<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Med.</journal-id>
<journal-title>Frontiers in Medicine</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Med.</abbrev-journal-title>
<issn pub-type="epub">2296-858X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmed.2022.845806</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Medicine</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>The Impact of Total Variation Regularized Expectation Maximization Reconstruction on <sup>68</sup>Ga-DOTA-TATE PET/CT Images in Patients With Neuroendocrine Tumor</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Liu</surname> <given-names>Lin</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1617317/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname> <given-names>Hanxiang</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Xu</surname> <given-names>Shijie</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1621865/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname> <given-names>Shumao</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tao</surname> <given-names>Yi</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mok</surname> <given-names>Greta S. P.</given-names></name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1651965/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Chen</surname> <given-names>Yue</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/683244/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University</institution>, <addr-line>Luzhou</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province</institution>, <addr-line>Luzhou</addr-line>, <country>China</country></aff>
<aff id="aff3"><sup>3</sup><institution>Academician (Expert) Workstation of Sichuan Province</institution>, <addr-line>Luzhou</addr-line>, <country>China</country></aff>
<aff id="aff4"><sup>4</sup><institution>United Imaging Healthcare</institution>, <addr-line>Shanghai</addr-line>, <country>China</country></aff>
<aff id="aff5"><sup>5</sup><institution>Biomedical Imaging Laboratory (BIG), Department of Electrical and Computer Engineering, Faculty of Science and Technology, University of Macau, Taipa</institution>, <addr-line>Macao SAR</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Philipp Lohmann, Institute of Neuroscience and Medicine, Germany</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Ismini C. Mainta, Geneva University Hospitals (HUG), Switzerland; Virginia Liberini, University of Turin, Italy</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Yue Chen <email>chenyue5523&#x00040;126.com</email></corresp>
<fn fn-type="other" id="fn001"><p>This article was submitted to Nuclear Medicine, a section of the journal Frontiers in Medicine</p></fn>
<fn fn-type="equal" id="fn002"><p>&#x02020;These authors have contributed equally to this work</p></fn></author-notes>
<pub-date pub-type="epub">
<day>11</day>
<month>03</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>9</volume>
<elocation-id>845806</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>12</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>02</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2022 Liu, Liu, Xu, Zhang, Tao, Mok and Chen.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Liu, Liu, Xu, Zhang, Tao, Mok and Chen</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license> </permissions>
<abstract>
<sec>
<title>Objective</title>
<p>The aim of this study was to investigate the effects of the total variation regularized expectation maximization (TVREM) reconstruction on improving <sup>68</sup>Ga-DOTA-TATE PET/CT images compared to the ordered subset expectation maximization (OSEM) reconstruction.</p></sec>
<sec>
<title>Method</title>
<p>A total of 17 patients with neuroendocrine tumors who underwent clinical <sup>68</sup>Ga-DOTA-TATE PET/CT were involved in this study retrospectively. The PET images were acquired with either 3 min-per-bed (min/bed) acquisition time and reconstructed with OSEM (2 iterations, 20 subsets, and a 3.2-mm Gaussian filter) and TVREM (seven penalization factors = 0.01, 0.07, 0.14, 0.21, 0.28, 0.35, and 0.42) for 2 and 3 min-per-bed (min/bed) acquisition time using list-mode. The SUV<sub>mean</sub> of the liver, background variability (BV), signal-to-noise ratios (SNR), SUV<sub>max</sub> of the lesions and tumor-to-background ratios (TBR) were measured. The mean percentage difference in the SNR and TBR between TVREM with difference penalization factors and OSEM was calculated. Qualitative image quality was evaluated by two experienced radiologists using a 5-point score scale (5-excellent, 1-poor).</p></sec>
<sec>
<title>Results</title>
<p>In total, 63 lesions were analyzed in this study. The SUV<sub>mean</sub> of the liver did not differ significantly between TVREM and OSEM. The BV of all TVREM groups was lower than OSEM groups (all <italic>p</italic> &#x0003C; 0.05), and the BV of TVREM 2 min/bed group with penalization factor of 0.21 was considered comparable to OSEM 3 min/bed group (<italic>p</italic> = 0.010 and 0.006). The SNR, SUV<sub>max</sub> and TBR were higher for all TVREM groups compared to OSEM groups (all <italic>p</italic> &#x0003C; 0.05). The mean percentage difference in the SNR and TBR was larger for small lesions (&#x0003C;10 mm) than that for medium (&#x02265;10 mm but &#x0003C; 20 mm) and large lesions (&#x02265;20 mm). The highest image quality score was given to TVREM 2 min/bed group with penalization factor of 0.21 (3.77 &#x000B1; 0.26) and TVREM 3 min/bed group with penalization factor of 0.35 (3.77 &#x000B1; 0.26).</p></sec>
<sec>
<title>Conclusion</title>
<p>TVREM could reduce image noise, improve the SNR, SUV<sub>max</sub> and TBR of the lesions, and has the potential to preserves the image quality with shorter acquisition time.</p></sec></abstract>
<kwd-group>
<kwd>PET/CT</kwd>
<kwd><sup>68</sup>Ga-DOTA-TATE</kwd>
<kwd>TVREM</kwd>
<kwd>OSEM</kwd>
<kwd>image quality</kwd>
</kwd-group>
<counts>
<fig-count count="4"/>
<table-count count="3"/>
<equation-count count="4"/>
<ref-count count="22"/>
<page-count count="8"/>
<word-count count="4626"/>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>Introduction</title>
<p>Neuroendocrine tumors (NETs) are a heterogeneous group of cancers derived from the diffuse neuroendocrine system. Neuroendocrine cells are distributed in every organ, the primary NET may occur in any part of the human body, and therefore early diagnosis of NET is very important for treatment (<xref ref-type="bibr" rid="B1">1</xref>). NET&#x00027;s early diagnosis methods include multiple CT, MRI, and endoscopic ultrasound. However, the specificity and sensitivity of these methods to NET are not high. One of the characteristics of neuroendocrine tumors is the high expression of somatostatin receptors (SSTR) (<xref ref-type="bibr" rid="B2">2</xref>). SSTR-expression tends to correlate inversely with tumor grade and differentiation, and consequently, the role of SRI is more limited in high grade and particularly in poorly differentiated carcinomas (<xref ref-type="bibr" rid="B3">3</xref>). Different types of tumors, primary tumors at different locations, and tumors in different differentiation grades have different somatostatin receptors over-expressed. There are 5 somatostatin receptors (SSTR 1-5) widely expressed in both normal tissues and tumors. In most tumors, SST2 and 5 are usually over-expressed (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>). This expression enables imaging with high sensitivity using PET with radioactively labeled somatostatin analogs such as <sup>68</sup>Ga-DOTA-TATE. PET with <sup>68</sup>Ga-labeled somatostatin ligands is well-established as a tool for localizing the primary tumor in metastatic NET (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>).</p>
<p>The radionuclide, the performance of the equipment, and the reconstruction algorithm are important factors that affect the precise positioning of the lesion. Ordered subsets expectation maximization (OSEM) is the clinical standard reconstruction method. However, due to the special requirements for noise and reconstruction time in clinical applications, the iteration of OSEM must be stopped before converging. This always leads to underestimation of radio-tracer uptake and low contrast of the lesion. Bayesian penalized likelihood reconstruction (BPL) can reduce image noise and increase lesion contrast compared to OSEM reconstruction (<xref ref-type="bibr" rid="B8">8</xref>&#x02013;<xref ref-type="bibr" rid="B10">10</xref>). Total variation regularized expectation maximization (TVREM), a new BPL algorithm, was introduced recently (HYPER Iterative, United Imaging Healthcare). Related studies have shown that TVREM algorithm in <sup>68</sup>Ga-PSMA imaging can ensure image quality while shortening the acquisition time (<xref ref-type="bibr" rid="B11">11</xref>). Therefore, as a BPL algorithm, TVREM has the potential to further increase the detection rate of lesions, shorten the acquisition time or reduce the dose (reduce administrated dose) for <sup>68</sup>Ga-DOTA-TATE PET imaging.</p>
<p>The purpose of this research is to explore the effect of TVREM algorithm on <sup>68</sup>Ga-DOTA-TATE PET/CT image quality, and the possibility of shortening the acquisition time and reducing the radiation burden.</p></sec>
<sec id="s2">
<title>Methods and Materials</title>
<sec>
<title>Study Population</title>
<p>Between March 1st, 2021 and May 30th, 2021, 17 patients with neuroendocrine tumors undergoing <sup>68</sup>Ga-DOTA-TATE PET/CT were enrolled in this study retrospectively. The study was approved by the ethics committee of the Affiliated Hospital of Southwest Medical University and was in accordance with the 1964 Helsinki declaration and its later amendments. The informed consent of this retrospective study was waived.</p></sec>
<sec>
<title>Preparation of <sup>68</sup>Ga-DOTA-TATE</title>
<p><sup>68</sup>Ga stock solution was made by rinsing the <sup>68</sup>Ga generator using 4 mL of 0.05 mol/L hydrochloric acid. The pH value was adjusted to 3.5&#x02013;4.0 with sodium acetate (0.25 mol/L). Twenty &#x003BC;g of DOTA-TATE (ABX, Germany) was added to the solution and mixed, which was then heated at 95&#x000B0;C for 10 min. The solution was first purified by a Sep-Pak C18 column, and then was filtered using a sterile filter to obtain <sup>68</sup>Ga-DOTA-TATE injection after washing the column with 50% ethanol solution and saline solution. The radiochemical purity was &#x0003E;99% analyzed by a radioactive high performance liquid chromatography (Radio-HPLC).</p></sec>
<sec>
<title>Image Acquisition</title>
<p>For <sup>68</sup>Ga-DOTA-TATE PET/CT imaging, the activity of intravenously injected according to the patients&#x00027; weight (2.04 &#x000B1; 0.19 MBq/kg). PET/CT images were acquired after 50&#x02013;70 min of intravenous administration using a digital PET/CT scanner (uMI780, United Imaging Healthcare). A non-enhanced CT was used for attenuation correction of PET and anatomic localization. The CT parameters were as follows: 120 kV, 100 mAs, rotation of 0.8 s, and 3-mm slice thickness. After CT scanning, a whole-body PET scan was performed with 5&#x02013;6 bed positions and 3 min/bed.</p>
<p>Attenuation corrected images were reconstructed with OSEM and TVREM. All images were reconstructed with time of flight (TOF), point spread function model (PSF), 600 mm field of view (FOV), 128 &#x000D7; 128 matrix, and slice thickness 3.0 mm. The OSEM reconstruction was performed with 2 iterations, 20 subsets and 3.2 mm of full width at half maximum (FWHM). Reconstruction with TVREM was performed with seven penalization factors: 0.01, 0.07, 0.14, 0.21, 0.28, 0.35, and 0.42. List-mode data were re-binned using the first 2 min /bed of the data and reconstructed with the same parameters.</p>
<p>In total, there were 16 groups of PET images in the final evaluation. We named these groups as OSEM_2 and OSEM_3 for OSEM with 2 and 3 min/bed; R201, R207, R214, R221, R228, R235, R242 for TVREM with different factors (0.01&#x02013;0.42 for 2 min/bed) and R301-R342 for TVREM with factors (0.01&#x02013;0.42 for 3 min/bed).</p></sec>
<sec>
<title>Clinical Studies Analysis</title>
<p>All the images were evaluated by an experienced nuclear medicine doctor with HERMES (HERMES, Stockholm, Sweden), and the regions of interest (ROI) were drawn on transaxial images around the tumor lesions to perform a semiquantitative analysis. A spherical (approximated 3 cm in diameter) in the right liver lobe was used as the activity background for each patient. The mean standardized uptake value (SUV<sub>mean</sub>) and the standard deviation (SD) of liver were recorded. Background variability (BV) was used as parameter to evaluate the image noise level and calculated as follow:</p>
<disp-formula id="E1"><label>(1)</label><mml:math id="M1"><mml:mtable class="eqnarray" columnalign="right center left"><mml:mtr><mml:mtd><mml:mi>B</mml:mi><mml:mi>V</mml:mi><mml:mo>=</mml:mo><mml:mi>S</mml:mi><mml:mi>D</mml:mi><mml:mo>/</mml:mo><mml:mi>S</mml:mi><mml:mi>U</mml:mi><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula>
<p>Maximum SUV (SUV<sub>max</sub>) values of lesions were recorded. Signal-to-noise ratios (SNR) and tumor-to-background ratios (TBR) were calculated as follows:</p>
<disp-formula id="E2"><label>(2)</label><mml:math id="M"><mml:mrow><mml:mi>S</mml:mi><mml:mi>N</mml:mi><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy='false'>(</mml:mo><mml:mi>S</mml:mi><mml:mi>U</mml:mi><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi>max</mml:mi></mml:mrow></mml:msub><mml:mtext>&#x000A0;of&#x000A0;lesion)</mml:mtext><mml:mo>/</mml:mo><mml:mi>B</mml:mi><mml:mi>V</mml:mi></mml:mrow></mml:math></disp-formula>
<disp-formula id="E3"><label>(3)</label><mml:math id="M3"><mml:mrow><mml:mi>T</mml:mi><mml:mi>B</mml:mi><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy='false'>(</mml:mo><mml:mi>S</mml:mi><mml:mi>U</mml:mi><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi>max</mml:mi></mml:mrow></mml:msub><mml:mtext>&#x000A0;of&#x000A0;lesion)</mml:mtext><mml:mo>/</mml:mo><mml:mo stretchy='false'>(</mml:mo><mml:mi>S</mml:mi><mml:mi>U</mml:mi><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mtext>&#x000A0;of&#x000A0;liver)</mml:mtext></mml:mrow></mml:math></disp-formula>
<p>Lesions were also divided and compared according to their size (diameter &#x0003C;10 mm, &#x02265;10 mm but &#x0003C;20 mm, and &#x02265;20 mm). The diameter of lesions were calculated as follows:</p>
<disp-formula id="E4"><label>(4)</label><mml:math id="M4"><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>3</mml:mn><mml:msqrt><mml:mrow><mml:mo stretchy='false'>(</mml:mo><mml:mi>V</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mn>4</mml:mn><mml:mi>&#x003C0;</mml:mi><mml:mo stretchy='false'>)</mml:mo><mml:mo>&#x000D7;</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msqrt><mml:mo>&#x000D7;</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:math></disp-formula>
<p>where the volume of lesions was measured on PET imgaes.</p></sec>
<sec>
<title>Clinical Evaluation</title>
<p>Two experienced nuclear physicians evaluated the image quality of <sup>68</sup>Ga-DOTA-TATE PET images reconstructed using OSEM and TVREM independently on a commercial workstation (uWS-MI R004, United Imaging Healthcare). The nuclear physicians evaluated the images using a 5-point scale without knowing the reconstruction parameters (<xref ref-type="table" rid="T1">Table 1</xref>). The image of 5-point was with excellent image quality, almost free of noise, ideal contrast and sharp border. The image of 4-point was with good image quality, and its noise did not affect the identification and diagnosis of the lesion at all. The image of 3-point was with moderate image quality, obvious noise, and sufficient lesion delineation to make a diagnosis. The image of 2-point was barely acceptable, and the noise was large, which affected the diagnosis. The image of 1-point had the worst image quality and could not be used for diagnosis at all.</p>
<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption><p>The 5-point scale of image quality.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th valign="top" align="left"><bold>Scores</bold></th>
<th valign="top" align="left"><bold>Descriptions</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">5</td>
<td valign="top" align="left">Excellent image quality, almost free of noise, ideal contrast and sharp border</td>
</tr>
<tr>
<td valign="top" align="left">4</td>
<td valign="top" align="left">Good image quality, and its noise did not affect the identification and diagnosis of the lesion at all</td>
</tr>
<tr>
<td valign="top" align="left">3</td>
<td valign="top" align="left">Moderate image quality, obvious noise, and sufficient lesion delineation to make a diagnosis</td>
</tr>
<tr>
<td valign="top" align="left">2</td>
<td valign="top" align="left">Barely acceptable, and the noise was large, which affected the diagnosis</td>
</tr>
<tr>
<td valign="top" align="left">1</td>
<td valign="top" align="left">The worst image quality and could not be used for diagnosis at all</td>
</tr>
</tbody>
</table>
</table-wrap></sec>
<sec>
<title>Statistical Analysis</title>
<p>SPSS 22.0 statistical analysis software (IBM, Armonk, NY, USA) was used for statistical analysis, and Graphpad8.0 was used for graphing. The data were presented as mean &#x000B1; SD. The SUV of OSEM_3 was served as the reference for the comparison between different reconstruction groups. Shapiro-Wilk test were used to test the normal distribution of data. Paired samples were compared using the Wilcoxon signed-rank test and paired <italic>t</italic>-test. The inter-evaluator agreement was measured by Cohen&#x00027;s &#x003BA;. A <italic>p</italic> &#x0003C; 0.05 was considered significant.</p></sec></sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<p>A total of 17 patients (7 women and 10 men; mean age &#x000B1; SD, 48 &#x000B1; 17 years) with suspicion and diagnosis of NET were enrolled and the presence of lesions was confirmed by CT, MRI, <sup>18</sup>F-FDG PET and biochemical evidence of NETs. The characteristics of the study population were summarized in <xref ref-type="table" rid="T2">Table 2</xref>.</p>
<table-wrap position="float" id="T2">
<label>Table 2</label>
<caption><p>Characteristics of study population.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th valign="top" align="left"><bold>Patient number</bold></th>
<th valign="top" align="center"><bold>Age (years)</bold></th>
<th valign="top" align="center"><bold>Gender</bold></th>
<th valign="top" align="left"><bold>Tumor location</bold></th>
<th valign="top" align="center"><bold>Ki-67</bold></th>
<th valign="top" align="center"><bold>NET grade</bold></th>
<th valign="top" align="center"><bold>The number of lesions</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">1</td>
<td valign="top" align="center">47</td>
<td valign="top" align="center">F</td>
<td valign="top" align="left">Pancreas NET</td>
<td valign="top" align="center">3%</td>
<td valign="top" align="center">G2</td>
<td valign="top" align="center">7</td>
</tr>
<tr>
<td valign="top" align="left">2</td>
<td valign="top" align="center">44</td>
<td valign="top" align="center">F</td>
<td valign="top" align="left">Adrenal pheochromocytoma</td>
<td valign="top" align="center">20%</td>
<td valign="top" align="center">G2</td>
<td valign="top" align="center">7</td>
</tr>
<tr>
<td valign="top" align="left">3</td>
<td valign="top" align="center">38</td>
<td valign="top" align="center">M</td>
<td valign="top" align="left">Adrenal pheochromocytoma</td>
<td valign="top" align="center">8%</td>
<td valign="top" align="center">G2</td>
<td valign="top" align="center">5</td>
</tr>
<tr>
<td valign="top" align="left">4</td>
<td valign="top" align="center">57</td>
<td valign="top" align="center">M</td>
<td valign="top" align="left">Pancreas NET</td>
<td valign="top" align="center">5%</td>
<td valign="top" align="center">G2</td>
<td valign="top" align="center">7</td>
</tr>
<tr>
<td valign="top" align="left">5</td>
<td valign="top" align="center">38</td>
<td valign="top" align="center">F</td>
<td valign="top" align="left">CBT</td>
<td valign="top" align="center">3%</td>
<td valign="top" align="center">G2</td>
<td valign="top" align="center">7</td>
</tr>
<tr>
<td valign="top" align="left">6</td>
<td valign="top" align="center">31</td>
<td valign="top" align="center">F</td>
<td valign="top" align="left">Pancreas NET</td>
<td valign="top" align="center">10%</td>
<td valign="top" align="center">G2</td>
<td valign="top" align="center">3</td>
</tr>
<tr>
<td valign="top" align="left">7</td>
<td valign="top" align="center">34</td>
<td valign="top" align="center">M</td>
<td valign="top" align="left">Pancreas NET</td>
<td valign="top" align="center">10%</td>
<td valign="top" align="center">G2</td>
<td valign="top" align="center">1</td>
</tr>
<tr>
<td valign="top" align="left">8</td>
<td valign="top" align="center">48</td>
<td valign="top" align="center">M</td>
<td valign="top" align="left">Pancreas NET</td>
<td valign="top" align="center">6%</td>
<td valign="top" align="center">G2</td>
<td valign="top" align="center">3</td>
</tr>
<tr>
<td valign="top" align="left">9</td>
<td valign="top" align="center">27</td>
<td valign="top" align="center">F</td>
<td valign="top" align="left">Pancreas NET</td>
<td valign="top" align="center">2%</td>
<td valign="top" align="center">G2</td>
<td valign="top" align="center">2</td>
</tr>
<tr>
<td valign="top" align="left">10</td>
<td valign="top" align="center">30</td>
<td valign="top" align="center">M</td>
<td valign="top" align="left">Pelvic NET</td>
<td valign="top" align="center">8%</td>
<td valign="top" align="center">G2</td>
<td valign="top" align="center">7</td>
</tr>
<tr>
<td valign="top" align="left">11</td>
<td valign="top" align="center">64</td>
<td valign="top" align="center">F</td>
<td valign="top" align="left">Pancreas NET</td>
<td valign="top" align="center">1%</td>
<td valign="top" align="center">G1</td>
<td valign="top" align="center">2</td>
</tr>
<tr>
<td valign="top" align="left">12</td>
<td valign="top" align="center">15</td>
<td valign="top" align="center">F</td>
<td valign="top" align="left">Hypophysoma</td>
<td valign="top" align="center">10%</td>
<td valign="top" align="center">G2</td>
<td valign="top" align="center">1</td>
</tr>
<tr>
<td valign="top" align="left">13</td>
<td valign="top" align="center">63</td>
<td valign="top" align="center">M</td>
<td valign="top" align="left">Pheochromocytoma</td>
<td valign="top" align="center">12%</td>
<td valign="top" align="center">G2</td>
<td valign="top" align="center">1</td>
</tr>
<tr>
<td valign="top" align="left">14</td>
<td valign="top" align="center">67</td>
<td valign="top" align="center">M</td>
<td valign="top" align="left">Highly differentiated neuroendocrine tumor of the left laryngeal wall</td>
<td valign="top" align="center">10%</td>
<td valign="top" align="center">G2</td>
<td valign="top" align="center">1</td>
</tr>
<tr>
<td valign="top" align="left">15</td>
<td valign="top" align="center">73</td>
<td valign="top" align="center">M</td>
<td valign="top" align="left">Mediastinal NET</td>
<td valign="top" align="center">80&#x02013;90%</td>
<td valign="top" align="center">G3</td>
<td valign="top" align="center">2</td>
</tr>
<tr>
<td valign="top" align="left">16</td>
<td valign="top" align="center">66</td>
<td valign="top" align="center">M</td>
<td valign="top" align="left">Small cell NET of the left neck</td>
<td valign="top" align="center">40%</td>
<td valign="top" align="center">G3</td>
<td valign="top" align="center">4</td>
</tr>
<tr>
<td valign="top" align="left">17</td>
<td valign="top" align="center">75</td>
<td valign="top" align="center">M</td>
<td valign="top" align="left">Left groin NET</td>
<td valign="top" align="center">20%</td>
<td valign="top" align="center">G2</td>
<td valign="top" align="center">3</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>NET, neuroendocrine tumor; CBT, carotid body tumor</italic>.</p>
</table-wrap-foot>
</table-wrap>
<sec>
<title>Lesion Analysis</title>
<p>In total, 63 lesions were identified in both reconstructions. The lesions&#x00027; diameter ranged from 7.0 to 60.0 mm. The mean values of SUV<sub>mean</sub> were not significant different between TVREM and OSEM (all <italic>p</italic> &#x0003E; 0.80). The mean values of BV in OSME_2 and OSEM_3 were 8.2 &#x000B1; 1.9% and 7.2 &#x000B1; 1.9%, the BV in TVREM groups decreased with the increase of penalization factors and the BV of R221 group was considered comparable to OSEM_3. The SUV<sub>max</sub>, SNR, and TBR were higher in all TVREM groups than OSEM (all <italic>p</italic> &#x0003C; 0.05). The SNR increased with the increase of penalization factor. Moreover, the SUV<sub>max</sub> and TBR of the lesions decreased as the penalization factors increased (<xref ref-type="table" rid="T3">Table 3</xref>).</p>
<table-wrap position="float" id="T3">
<label>Table 3</label>
<caption><p>SUV<sub>mean</sub>, background variability, SUV<sub>max</sub>, SNR and TBR of the clinical study.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th/>
<th valign="top" align="center"><bold>Background SUV<sub><bold>mean</bold></sub></bold></th>
<th valign="top" align="center"><bold>Background variability %</bold></th>
<th valign="top" align="center"><bold>SUV<sub><bold>max</bold></sub></bold></th>
<th valign="top" align="center"><bold>SNR</bold></th>
<th valign="top" align="center"><bold>TBR</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">OSEM_2</td>
<td valign="top" align="center">7.62</td>
<td valign="top" align="center">8%</td>
<td valign="top" align="center">19.06</td>
<td valign="top" align="center">268.20</td>
<td valign="top" align="center">2.62</td>
</tr>
<tr>
<td valign="top" align="left">R201</td>
<td valign="top" align="center">7.56</td>
<td valign="top" align="center">8%</td>
<td valign="top" align="center">20.82</td>
<td valign="top" align="center">281.92</td>
<td valign="top" align="center">2.88</td>
</tr>
<tr>
<td valign="top" align="left">R207</td>
<td valign="top" align="center">7.56</td>
<td valign="top" align="center">8%</td>
<td valign="top" align="center">20.78</td>
<td valign="top" align="center">294.46</td>
<td valign="top" align="center">2.87</td>
</tr>
<tr>
<td valign="top" align="left">R214</td>
<td valign="top" align="center">7.57</td>
<td valign="top" align="center">8%</td>
<td valign="top" align="center">20.73</td>
<td valign="top" align="center">309.71</td>
<td valign="top" align="center">2.86</td>
</tr>
<tr>
<td valign="top" align="left">R221</td>
<td valign="top" align="center">7.57</td>
<td valign="top" align="center">7%</td>
<td valign="top" align="center">20.68</td>
<td valign="top" align="center">325.63</td>
<td valign="top" align="center">2.85</td>
</tr>
<tr>
<td valign="top" align="left">R228</td>
<td valign="top" align="center">7.60</td>
<td valign="top" align="center">7%</td>
<td valign="top" align="center">20.63</td>
<td valign="top" align="center">341.02</td>
<td valign="top" align="center">2.85</td>
</tr>
<tr>
<td valign="top" align="left">R235</td>
<td valign="top" align="center">7.60</td>
<td valign="top" align="center">7%</td>
<td valign="top" align="center">20.57</td>
<td valign="top" align="center">357.25</td>
<td valign="top" align="center">2.84</td>
</tr>
<tr>
<td valign="top" align="left">R242</td>
<td valign="top" align="center">7.60</td>
<td valign="top" align="center">6%</td>
<td valign="top" align="center">20.53</td>
<td valign="top" align="center">373.98</td>
<td valign="top" align="center">2.83</td>
</tr>
<tr>
<td valign="top" align="left">OSEM_3</td>
<td valign="top" align="center">7.56</td>
<td valign="top" align="center">7%</td>
<td valign="top" align="center">18.94</td>
<td valign="top" align="center">297.89</td>
<td valign="top" align="center">2.61</td>
</tr>
<tr>
<td valign="top" align="left">R301</td>
<td valign="top" align="center">7.61</td>
<td valign="top" align="center">8%</td>
<td valign="top" align="center">20.98</td>
<td valign="top" align="center">299.67</td>
<td valign="top" align="center">2.89</td>
</tr>
<tr>
<td valign="top" align="left">R307</td>
<td valign="top" align="center">7.61</td>
<td valign="top" align="center">8%</td>
<td valign="top" align="center">20.95</td>
<td valign="top" align="center">305.71</td>
<td valign="top" align="center">2.89</td>
</tr>
<tr>
<td valign="top" align="left">R314</td>
<td valign="top" align="center">7.58</td>
<td valign="top" align="center">7%</td>
<td valign="top" align="center">20.92</td>
<td valign="top" align="center">317.58</td>
<td valign="top" align="center">2.88</td>
</tr>
<tr>
<td valign="top" align="left">R321</td>
<td valign="top" align="center">7.58</td>
<td valign="top" align="center">7%</td>
<td valign="top" align="center">20.89</td>
<td valign="top" align="center">329.07</td>
<td valign="top" align="center">2.88</td>
</tr>
<tr>
<td valign="top" align="left">R328</td>
<td valign="top" align="center">7.62</td>
<td valign="top" align="center">7%</td>
<td valign="top" align="center">20.90</td>
<td valign="top" align="center">339.40</td>
<td valign="top" align="center">2.88</td>
</tr>
<tr>
<td valign="top" align="left">R335</td>
<td valign="top" align="center">7.61</td>
<td valign="top" align="center">7%</td>
<td valign="top" align="center">20.85</td>
<td valign="top" align="center">352.69</td>
<td valign="top" align="center">2.88</td>
</tr>
<tr>
<td valign="top" align="left">R342</td>
<td valign="top" align="center">7.61</td>
<td valign="top" align="center">6%</td>
<td valign="top" align="center">20.81</td>
<td valign="top" align="center">364.06</td>
<td valign="top" align="center">2.87</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>SUV, standardized uptake value; SNR, signal-to-noise ratio; TBR, tumor-to-background ratio</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p><xref ref-type="fig" rid="F1">Figure 1</xref> shows the results of lesions SNR and TBR. When lesions were divided into different groups according to their sizes, the SNR of small lesions (&#x0003C;10 mm) in most TVREM groups for 2 min/bed were higher than OSEM_3 significantly (all <italic>p</italic> &#x0003C; 0.05) except for R201 (<italic>p</italic> = 0.25), and the TBR of small lesions (&#x0003C;10 mm) in all TVREM groups were higher than OSEM significantly (all <italic>p</italic> &#x0003C; 0.05).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p>SNR and TBR based on different size of lesions: diameter &#x0003C; 10 mm <bold>(A,D)</bold>, 10 mm &#x02264; diameter &#x0003C; 20 mm <bold>(B,E)</bold>, diameter &#x02265; 20 mm <bold>(C,F)</bold>. The quartiles are represented by the bottom and top line, respectively. Median is middle line. SNR, signal-to-noise ratio; TBR, tumor-to-background ratio.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmed-09-845806-g0001.tif"/>
</fig>
<p>For medium lesions (&#x02265; 10 mm but &#x0003C;20 mm), there were not significantly differences in the SNR between most TVREM groups and OSEM_3 except for R235 (<italic>p</italic> = 0.02) and R242 (<italic>p</italic> = 0.01), and the SNR of R214 was considered comparable to OSEM_3. The TBR of lesions in TVREM were higher than OSEM_3 significantly (all <italic>p</italic> &#x0003C; 0.05) except for R228 (<italic>p</italic> = 0.05), R235 (<italic>p</italic> = 0.06), and R242 (<italic>p</italic> = 0.07).</p>
<p>For large lesions (&#x02265;20 mm), there were not significantly differences in the SNR and TBR between TVREM groups and OSEM_3 (all <italic>p</italic> &#x0003E; 0.05).</p>
<p>The mean percentage difference in the SNR and TBR between TVREM with difference penalization factors and OSEM_3 were shown in <xref ref-type="fig" rid="F2">Figure 2</xref>. The mean percentage difference in the SNR of R242 was 19.25 &#x000B1; 22.76% for small lesions, 12.79 &#x000B1; 18.40% for medium lesions, and 18.13%&#x000B1; 9.80% for large lesions compared to OSEM_3. The mean percentage difference in the TBR of R201 was 14.31 &#x000B1; 9.66% for small lesions, 8.06 &#x000B1; 8.65% for medium lesions, and 8.88 &#x000B1; 7.41% for large lesions compared to OSEM_3. A representative case for lesions with different sizes is shown in <xref ref-type="fig" rid="F3">Figure 3</xref>.</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption><p>Mean and SD (error line) of the percentage difference in SNR and TBR of TVREM compared to OSEM_3 according to lesion size: diameter &#x0003C;10 mm <bold>(A,D)</bold>, 10 mm &#x02264; diameter &#x0003C;20 mm <bold>(B,E)</bold>, diameter &#x02265;20 mm <bold>(C,F)</bold>. SD, standard deviation; SNR, signal-to-noise ratio; TBR, tumor-to-background ratio; TVREM, total variation regularized expectation maximization; OSEM, ordered subset expectation maximization.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmed-09-845806-g0002.tif"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption><p>Patient images reconstructed by different algorithms. Patient with Adrenal pheochromocytoma (female; 44-years-old). <bold>(A)</bold> Maximum-intensity-projection <sup>68</sup>Ga-DOTATAE PET shows multiple metastases. <bold>(B)</bold> Fused PET/CT images. <bold>(C&#x02013;F)</bold> PET images with different size lesions in OSEM_2, OSEM_3, R221, and R314 groups. The diameter of the lesion was 8.40 mm in the first row, 16.86 mm in the second row, and 25.00 mm in the third row.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmed-09-845806-g0003.tif"/>
</fig>
<p>The results of subject evaluation for image quality were shown in <xref ref-type="fig" rid="F4">Figure 4</xref>. The image quality scores of all the TVREM groups were higher than OSEM groups. R221 and R228 had higher image quality scores compared to OSEM_3 (<italic>p</italic> = 0.010 and 0.006), and the image quality scores of R328, R335, and R342 were significantly higher than OSEM_3 (<italic>p</italic> = 0.019, 0.004 and 0.029). The highest score was given to R221 (3.77 &#x000B1; 0.26) in 2 min/bed groups and R335 (3.77 &#x000B1; 0.26) in 3 min/bed groups. In all reconstruction series, the Kappa value of 0.45 indicated moderate reliability.</p>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption><p>The mean and standard deviation (error bar) of the image quality score for TVREM and OSEM groups. The highest score was given to R221 and R335 for 2 and 3 min/bed acquisition. TVREM, total variation regularized expectation maximization; OSEM, ordered subset expectation maximization.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmed-09-845806-g0004.tif"/>
</fig></sec></sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>In our study, we evaluated the impact of TVREM on the image quality of <sup>68</sup>Ga-DOTA-TATE. There was no significant difference in the liver SUV<sub>mean</sub> between TVREM and OSEM, and TVREM showed a significant improvement of SNR and TBR compared to OSEM, especially for small lesions with diameter &#x0003C;10 mm. Moreover, we found that SUV<sub>max</sub> values in TVREM were higher than that in OSEM significantly. TVREM with a penalization factor of 0.14 and 2 min/bed acquisition time could provide equivalent image quality compared to OSEM with 3 min/bed acquisition time.</p>
<p>It has been shown that BPL provided better image quality without affecting the background liver uptake and improved the lesions conspicuity (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>). Yoshie et al. showed that BPL reconstruction significantly improved the detection of small inconspicuous malignant tumors (diameter &#x0003C;10 mm) in the lung and improved the diagnostic performance of PET/CT (<xref ref-type="bibr" rid="B14">14</xref>). In our study, the results showed that the SNR and TBR of small lesions (diameter &#x0003C;10 mm) increased more than 3 and 6% in all TVREM groups compared to OSEM 3 min/bed. Those results were partly consistent with a previous study by Ewa et al. in which showed that BPL SUVs and TBR tend to be higher for small lesions (<xref ref-type="bibr" rid="B9">9</xref>). In addition, the SUV<sub>max</sub> of lesions in our study decreased with the increase of penalization factor, which was consistent with a previous study using <sup>18</sup>F-FDG PET/CT (<xref ref-type="bibr" rid="B15">15</xref>).</p>
<p>The capability of BPL algorithm of shortening acquisition time was reported in several studies (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>). A phantom and clinical study by Yang et al. showed that TVREM could improve the lesion contrast and lower image noise of <sup>68</sup>Ga-PSMA-11 PET/CT compared to OSEM and enable a fast acquisition with 2 min/bed with preserved image quality (<xref ref-type="bibr" rid="B10">10</xref>). Similarly, the results in our study showed that a penalization factor between 0.21 and 0.42 for TVREM with 2 min/bed acquisition time could attain equivalent or lower noise compared to OSEM with 3 min/bed acquisition time.</p>
<p>New image reconstruction methods could help in clinical practice by reducing acquisition times while maintaining accuracy (<xref ref-type="bibr" rid="B18">18</xref>), getting better image quality in obese patients (<xref ref-type="bibr" rid="B19">19</xref>), improving accurately identify of very small lesions (<xref ref-type="bibr" rid="B20">20</xref>), and underpinning the use of further new tools such as data driven gating which can help to differentiate malignant lesions from begin structures and injuries (<xref ref-type="bibr" rid="B21">21</xref>). And the most accurate reconstruction factor were likely depending on the count statistics and uptake pattern vary between the radionuclide and radiopharmaceutical (<xref ref-type="bibr" rid="B22">22</xref>). In our subjective evaluation, the image quality was assessed using a 5-grade scale by two radiologists. Our results showed that the higher quality score was given to TRVEM groups with the penalization factor ranged from 0.14 to 0.35 for 2 and 3 min/bed acquisition. In our study, the image noise and TBR decreased with the increase of penalization factor. Although the increase of the penalization factor could reduce more noise, it could also reduce the contrast of the lesion, which was reflected in the lower image quality scores of the high-level penalization factor groups.</p>
<p>Our study has some limitations. First, the patient population was relatively small; a larger and multicenter study should be involved in the future. Second, the experience of two radiologists who evaluated the images were different, and the agreement was not very high. Furthermore, there was no pathologic confirmation of most lesions. The biopsy results should be used to investigate whether the TVREM could improve the detection rate of lesion in further studies.</p></sec>
<sec sec-type="conclusions" id="s5">
<title>Conclusion</title>
<p>TVREM reconstruction algorithm can improve the SUV<sub>max</sub>, SNR and TBR and lower image noise of <sup>68</sup>Ga-DOTA-TATE compared to OSEM, especially for small lesions &#x0003C;10 mm in diameter. TVREM has the potential to preserve image quality in short acquisition time with penalization factors ranged from 0.14 to 0.35.</p></sec>
<sec sec-type="data-availability" id="s6">
<title>Data Availability Statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec>
<sec id="s7">
<title>Ethics Statement</title>
<p>The studies involving human participants were reviewed and approved by the Affiliated Hospital of Southwest Medical University. The patients/participants provided their written informed consent to participate in this study.</p></sec>
<sec id="s8">
<title>Author Contributions</title>
<p>LL conducted statistical analyses. LL and HL drafted the manuscript. SX, SZ, and YT collected cases. GM and YC provided critical review of the manuscript for key intellectual content. YC is the guarantor and as such, had full access to the data, and takes responsibility for its integrity and accuracy. All authors conceived and designed the study, interpreted the findings, and approved the final manuscript.</p></sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of Interest</title>
<p>SX is employed by Shanghai United Imaging Healthcare Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec>
<sec sec-type="disclaimer" id="s9">
<title>Publisher&#x00027;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec>
</body>
<back>
<ack><p>We are grateful to all the nuclear medicine professionals in the Affiliated Hospital of Southwest Medical University who helped with this research.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caplin</surname> <given-names>ME</given-names></name> <name><surname>Buscombe</surname> <given-names>JR</given-names></name> <name><surname>Hilson</surname> <given-names>AJ</given-names></name> <name><surname>Jones</surname> <given-names>AL</given-names></name> <name><surname>Watkinson</surname> <given-names>AF</given-names></name> <name><surname>Burroughs</surname> <given-names>AK</given-names></name></person-group>. <article-title>Carcinoid tumour</article-title>. <source>Lancet.</source> (<year>1998</year>) <volume>352</volume>:<fpage>799</fpage>&#x02013;<lpage>805</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(98)02286-7</pub-id><pub-id pub-id-type="pmid">9737302</pub-id></citation></ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pelosi</surname> <given-names>G</given-names></name> <name><surname>Volante</surname> <given-names>M</given-names></name> <name><surname>Papotti</surname> <given-names>M</given-names></name> <name><surname>Sonzogni</surname> <given-names>A</given-names></name> <name><surname>Masullo</surname> <given-names>M</given-names></name> <name><surname>Viale</surname> <given-names>G</given-names></name></person-group>. <article-title>Peptide receptors in neuroendocrine tumors of the lung as potential tools for radionuclide diagnosis and therapy</article-title>. <source>Q J Nucl Med Mol Imaging.</source> (<year>2006</year>) <volume>50</volume>:<fpage>272</fpage>&#x02013;<lpage>87</lpage>. <pub-id pub-id-type="pmid">17043625</pub-id></citation></ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haider</surname> <given-names>M</given-names></name> <name><surname>Al-Toubah</surname> <given-names>T</given-names></name> <name><surname>El-Haddad</surname> <given-names>G</given-names></name> <name><surname>Strosberg</surname> <given-names>J</given-names></name></person-group>. <article-title>Molecular imaging and radionuclide therapy of neuroendocrine tumors</article-title>. <source>Curr Opin Endocrinol Diabetes Obes.</source> (<year>2020</year>) <volume>27</volume>:<fpage>16</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1097/MED.0000000000000519</pub-id><pub-id pub-id-type="pmid">31789833</pub-id></citation></ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reubi</surname> <given-names>JC</given-names></name> <name><surname>Sch&#x000E4;r</surname> <given-names>JC</given-names></name> <name><surname>Waser</surname> <given-names>B</given-names></name> <name><surname>Wenger</surname> <given-names>S</given-names></name> <name><surname>Heppeler</surname> <given-names>A</given-names></name> <name><surname>Schmitt</surname> <given-names>JS</given-names></name> <etal/></person-group>. <article-title>Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use</article-title>. <source>Eur J Nucl Med.</source> (<year>2000</year>) <volume>27</volume>:<fpage>273</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1007/s002590050034</pub-id><pub-id pub-id-type="pmid">10774879</pub-id></citation></ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoyer</surname> <given-names>D</given-names></name> <name><surname>Bell</surname> <given-names>GI</given-names></name> <name><surname>Berelowitz</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>Classification and nomenclature of somatostatin receptors</article-title>. <source>Trends Pharmacol Sci.</source> (<year>1995</year>) <volume>16</volume>:<fpage>86</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/S0165-6147(00)88988-9</pub-id><pub-id pub-id-type="pmid">7792934</pub-id></citation></ref>
<ref id="B6">
<label>6.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Breeman</surname> <given-names>W</given-names></name> <name><surname>Blois</surname> <given-names>ED</given-names></name> <name><surname>Chan</surname> <given-names>HS</given-names></name> <name><surname>Epelbaum</surname> <given-names>J</given-names></name> <name><surname>Feniuk</surname> <given-names>W</given-names></name> <name><surname>Humphrey</surname> <given-names>PPA</given-names></name> <etal/></person-group>. <article-title>68Ga-labeled DOTA-peptides and 68Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives</article-title>. <source>Semin Nucl Med.</source> (<year>2011</year>) <volume>41</volume>:<fpage>314</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1053/j.semnuclmed.2011.02.001</pub-id><pub-id pub-id-type="pmid">21624565</pub-id></citation></ref>
<ref id="B7">
<label>7.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haug</surname> <given-names>AR</given-names></name> <name><surname>Cindea-Drimus</surname> <given-names>R</given-names></name> <name><surname>Auernhammer</surname> <given-names>CJ</given-names></name> <name><surname>Reincke</surname> <given-names>M</given-names></name> <name><surname>W&#x000E4;ngler</surname> <given-names>B</given-names></name> <name><surname>Uebleis</surname> <given-names>C</given-names></name> <etal/></person-group>. <article-title>The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors</article-title>. <source>J Nucl Med.</source> (<year>2012</year>) <volume>53</volume>:<fpage>1686</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.2967/jnumed.111.101675</pub-id><pub-id pub-id-type="pmid">22984220</pub-id></citation></ref>
<ref id="B8">
<label>8.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Teoh</surname> <given-names>EJ</given-names></name> <name><surname>McGowan</surname> <given-names>DR</given-names></name> <name><surname>Macpherson</surname> <given-names>RE</given-names></name> <name><surname>Bradley</surname> <given-names>KM</given-names></name> <name><surname>Gleeson</surname> <given-names>FV</given-names></name></person-group>. <article-title>Phantom and clinical evaluation of the Bayesian penalized likelihood reconstruction algorithm Q. Clear on an LYSO PET/CT system</article-title>. <source>J Nucl Med.</source> (<year>2015</year>) <volume>56</volume>:<fpage>1447</fpage>&#x02013;<lpage>522</lpage>. <pub-id pub-id-type="doi">10.2967/jnumed.115.159301</pub-id><pub-id pub-id-type="pmid">26159585</pub-id></citation></ref>
<ref id="B9">
<label>9.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spasic</surname> <given-names>E</given-names></name> <name><surname>Jehanno</surname> <given-names>N</given-names></name> <name><surname>Gomes</surname> <given-names>SB</given-names></name> <name><surname>Huchet</surname> <given-names>V</given-names></name> <name><surname>Luporsi</surname> <given-names>M</given-names></name> <name><surname>Mounat</surname> <given-names>TC</given-names></name></person-group>. <article-title>Phantom and clinical evaluation for new PET/CT reconstruction algorithm: Bayesian penalized likelihood reconstruction algorithm Q. Clear</article-title>. <source>J Nucl Med Radiat Ther.</source> (<year>2018</year>) <volume>9</volume>:<fpage>371</fpage>. <pub-id pub-id-type="doi">10.4172/2155-9619.1000371</pub-id></citation>
</ref>
<ref id="B10">
<label>10.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Witkowska-Patena</surname> <given-names>E</given-names></name> <name><surname>Budzy&#x00144;ska</surname> <given-names>A</given-names></name> <name><surname>Gizewska</surname> <given-names>A</given-names></name> <name><surname>Dziuk</surname> <given-names>M</given-names></name> <name><surname>Walecka-Mazur</surname> <given-names>A</given-names></name></person-group>. <article-title>Ordered subset expectation maximisation vs Bayesian penalised likelihood reconstruction algorithm in 18F-PSMA-1007 PET/CT</article-title>. <source>Ann Nucl Med.</source> (<year>2020</year>) <volume>34</volume>:<fpage>192</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s12149-019-01433-x</pub-id><pub-id pub-id-type="pmid">31902120</pub-id></citation></ref>
<ref id="B11">
<label>11.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>FJ</given-names></name> <name><surname>Ai</surname> <given-names>SY</given-names></name> <name><surname>Wu</surname> <given-names>R</given-names></name> <name><surname>Lv</surname> <given-names>Y</given-names></name> <name><surname>Xie</surname> <given-names>HF</given-names></name> <name><surname>Dong</surname> <given-names>Y</given-names></name> <etal/></person-group>. <article-title>Impact of total variation regularized expectation maximization reconstruction on the image quality of 68Ga-PSMA PET: a phantom and patient study</article-title>. <source>Br J Radiol</source>. (<year>2021</year>) <volume>94</volume>:<fpage>20201356</fpage>. <pub-id pub-id-type="doi">10.1259/bjr.20201356</pub-id><pub-id pub-id-type="pmid">33571001</pub-id></citation></ref>
<ref id="B12">
<label>12.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname> <given-names>S</given-names></name> <name><surname>Ross</surname> <given-names>SG</given-names></name> <name><surname>Asma</surname> <given-names>E</given-names></name> <name><surname>Miao</surname> <given-names>J</given-names></name> <name><surname>Jin</surname> <given-names>X</given-names></name> <name><surname>Cheng</surname> <given-names>L</given-names></name> <etal/></person-group>. <article-title>Quantitative comparison of OSEM and penalized likelihood image reconstruction using relative difference penalties for clinical PET</article-title>. <source>Phys Med Biol.</source> (<year>2015</year>) <volume>60</volume>:<fpage>5733</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1088/0031-9155/60/15/5733</pub-id><pub-id pub-id-type="pmid">26158503</pub-id></citation></ref>
<ref id="B13">
<label>13.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rogasch</surname> <given-names>JM</given-names></name> <name><surname>Suleiman</surname> <given-names>S</given-names></name> <name><surname>Hofheinz</surname> <given-names>F</given-names></name> <name><surname>Bluemel</surname> <given-names>S</given-names></name> <name><surname>Lukas</surname> <given-names>M</given-names></name> <name><surname>Amthauer</surname> <given-names>H</given-names></name> <etal/></person-group>. <article-title>Reconstructed spatial resolution and contrast recovery with Bayesian penalized likelihood reconstruction (QClear) for FDG-PET compared to time-of-flight (TOF) with point spread function (PSF)</article-title>. <source>EJNMMI Phys.</source> (<year>2020</year>) <volume>7</volume>:<fpage>2</fpage>. <pub-id pub-id-type="doi">10.1186/s40658-020-0270-y</pub-id><pub-id pub-id-type="pmid">31925574</pub-id></citation></ref>
<ref id="B14">
<label>14.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurita</surname> <given-names>Y</given-names></name> <name><surname>Ichikawa</surname> <given-names>Y</given-names></name> <name><surname>Nakanishi</surname> <given-names>T</given-names></name> <name><surname>Tomita</surname> <given-names>Y</given-names></name> <name><surname>Hasegawa</surname> <given-names>D</given-names></name> <name><surname>Murashima</surname> <given-names>S</given-names></name> <etal/></person-group>. <article-title>The value of Bayesian penalized likelihood reconstruction for improving lesion conspicuity of malignant lung tumors on 18F-FDG PET/CT: comparison with ordered subset expectation maximization reconstruction incorporating time-of-flight model and point spread function correction</article-title>. <source>Ann Nucl Med.</source> (<year>2020</year>) <volume>34</volume>:<fpage>272</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s12149-020-01446-x</pub-id><pub-id pub-id-type="pmid">32060780</pub-id></citation></ref>
<ref id="B15">
<label>15.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ter Voert</surname> <given-names>EEGW</given-names></name> <name><surname>Muehlematter</surname> <given-names>UJ</given-names></name> <name><surname>Delso</surname> <given-names>G</given-names></name> <name><surname>Pizzuto</surname> <given-names>DA</given-names></name> <name><surname>M&#x000FC;ller</surname> <given-names>J</given-names></name> <name><surname>Nagel</surname> <given-names>HW</given-names></name> <etal/></person-group>. <article-title>Quantitative performance and optimal regularization parameter in block sequential regularized expectation maximization reconstructions in clinical 68Ga-PSMA PET/MR</article-title>. <source>EJNMMI Res.</source> (<year>2018</year>) <volume>8</volume>:<fpage>70</fpage>. <pub-id pub-id-type="doi">10.1186/s13550-018-0414-4</pub-id><pub-id pub-id-type="pmid">30054750</pub-id></citation></ref>
<ref id="B16">
<label>16.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindstrom</surname> <given-names>E</given-names></name> <name><surname>Sundin</surname> <given-names>A</given-names></name> <name><surname>Trampal</surname> <given-names>C</given-names></name> <name><surname>Lindsjo</surname> <given-names>L</given-names></name> <name><surname>Ilan</surname> <given-names>E</given-names></name> <name><surname>Danfors</surname> <given-names>T</given-names></name> <etal/></person-group>. <article-title>Evaluation of penalized-likelihood estimation reconstruction on a digital time-of- flight PET/CT scanner for 18F-FDG whole-body examinations</article-title>. <source>J Nucl Med.</source> (<year>2018</year>) <volume>59</volume>:<fpage>1152</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.2967/jnumed.117.200790</pub-id><pub-id pub-id-type="pmid">29449445</pub-id></citation></ref>
<ref id="B17">
<label>17.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoshii</surname> <given-names>T</given-names></name> <name><surname>Miwa</surname> <given-names>K</given-names></name> <name><surname>Yamaguchi</surname> <given-names>M</given-names></name> <name><surname>Shimada</surname> <given-names>K</given-names></name> <name><surname>Wagatsuma</surname> <given-names>K</given-names></name> <name><surname>Yamao</surname> <given-names>T</given-names></name> <etal/></person-group>. <article-title>Optimization of a Bayesian penalized likelihood algorithm (QClear) for 18F-NaF bone PET/CT images acquired over shorter durations using a custom-designed phantom</article-title>. <source>EJNMMI Phys.</source> (<year>2020</year>) <volume>7</volume>:<fpage>56</fpage>. <pub-id pub-id-type="doi">10.1186/s40658-020-00325-8</pub-id><pub-id pub-id-type="pmid">32915344</pub-id></citation></ref>
<ref id="B18">
<label>18.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chicheportiche</surname> <given-names>A</given-names></name> <name><surname>Goshen</surname> <given-names>E</given-names></name> <name><surname>Godefroy</surname> <given-names>J</given-names></name> <name><surname>Grozinsky-Glasberg</surname> <given-names>S</given-names></name> <name><surname>Oleinikov</surname> <given-names>K</given-names></name> <name><surname>Meirovitz</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>Can a penalized-likelihood estimation algorithm be used to reduce the injected dose or the acquisition time in 68Ga-DOTATATE PET/CT studies?</article-title> <source>EJNMMI Phys.</source> (<year>2021</year>) <volume>8</volume>:<fpage>13</fpage>. <pub-id pub-id-type="doi">10.1186/s40658-021-00359-6</pub-id><pub-id pub-id-type="pmid">33580359</pub-id></citation></ref>
<ref id="B19">
<label>19.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zanoni</surname> <given-names>L</given-names></name> <name><surname>Argalia</surname> <given-names>G</given-names></name> <name><surname>Fortunati</surname> <given-names>E</given-names></name> <name><surname>Malizia</surname> <given-names>C</given-names></name> <name><surname>Allegri</surname> <given-names>V</given-names></name> <name><surname>Calabr&#x000F2;</surname> <given-names>D</given-names></name> <etal/></person-group>. <article-title>Can Q. clear reconstruction be used to improve [68 Ga]Ga-DOTANOC PET/CT image quality in overweight NEN patients?</article-title> <source>Eur J Nucl Med Mol Imaging</source>. (<year>2021</year>). <pub-id pub-id-type="doi">10.1007/s00259-021-05592-w.</pub-id> [In press].<pub-id pub-id-type="pmid">34693467</pub-id></citation></ref>
<ref id="B20">
<label>20.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liberini</surname> <given-names>V</given-names></name> <name><surname>Messerli</surname> <given-names>M</given-names></name> <name><surname>Husmann</surname> <given-names>L</given-names></name> <name><surname>Kudura</surname> <given-names>K</given-names></name> <name><surname>Gr&#x000FC;nig</surname> <given-names>H</given-names></name> <name><surname>Maurer</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>Improved detection of in-transit metastases of malignant melanoma with BSREM reconstruction in digital [18F]FDG PET/CT</article-title>. <source>Eur Radiol.</source> (<year>2021</year>) <volume>31</volume>:<fpage>8011</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1007/s00330-021-07852-7</pub-id><pub-id pub-id-type="pmid">33768288</pub-id></citation></ref>
<ref id="B21">
<label>21.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liberini</surname> <given-names>V</given-names></name> <name><surname>Kotasidis</surname> <given-names>F</given-names></name> <name><surname>Treyer</surname> <given-names>V</given-names></name> <name><surname>Messerli</surname> <given-names>M</given-names></name> <name><surname>Orita</surname> <given-names>E</given-names></name> <name><surname>Engel-Bicik</surname> <given-names>I</given-names></name> <etal/></person-group>. <article-title>Impact of PET data driven respiratory motion correction and BSREM reconstruction of 68Ga-DOTATATE PET/CT for differentiating neuroendocrine tumors (NET) and intrapancreatic accessory spleens (IPAS)</article-title>. <source>Sci Rep.</source> (<year>2021</year>) <volume>11</volume>:<fpage>2273</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-020-80855-4</pub-id><pub-id pub-id-type="pmid">33500455</pub-id></citation></ref>
<ref id="B22">
<label>22.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindstr&#x000F6;m</surname> <given-names>E</given-names></name> <name><surname>Lindsj&#x000F6;</surname> <given-names>L</given-names></name> <name><surname>Sundin</surname> <given-names>A</given-names></name> <name><surname>S&#x000F6;rensen</surname> <given-names>J</given-names></name> <name><surname>Lubberink</surname> <given-names>M</given-names></name></person-group>. <article-title>Evaluation of block-sequential regularized expectation maximization reconstruction of 68Ga-DOTATOC, 18F-fluoride, and 11C-acetate whole-body examinations acquired on a digital time-of-flight PET/CT scanner</article-title>. <source>EJNMMI Phys.</source> (<year>2020</year>) <volume>7</volume>:<fpage>40</fpage>. <pub-id pub-id-type="doi">10.1186/s40658-020-00310-1</pub-id><pub-id pub-id-type="pmid">32542512</pub-id></citation></ref>
</ref-list>
</back>
</article>